Work

Modern possibilities of drug therapy for early and locally advanced triple negative breast cancer

Year: 2026

Type: article

Abstract: Triple negative breast cancer remains the subtype of breast cancer with the highest rates of recurrence and mortality. Research in the field of tumor biology has led to identification of subgroups of patients with specific molecular features, which has led to the development and approval of many new targeted treatments for this disease. This review considers current options for the treatment of locally advanced forms of breast cancer at the neoadjuvant stage – the use of carboplatin, targeted therapy with vascular endothelial growth factor inhibitors and immunotherapy. It discusses the practical problems and unanswered questions that arise in connection with the approval of neoadjuvant immunotherapy, and describes the approach used in the clinical practice to use various treatment options and the possibility of combining them to achieve the best early and long-term results.

Source: MD-Onco

DOI: 10.17650/2782-3202-2026-6-1-14-23

Authors: A. S. Belokhvostova, A. B. Galitsyna, A. A. Sofiychuk, N. A. Falaleeva, A. I.A. Abdulkhalim

Institutions: Ministry of Health of the Russian Federation, Medical Radiological Research Center, Obninsk Institute for Nuclear Power Engineering, National Research Nuclear University MEPhI, Peoples' Friendship University of Russia

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: hybrid

OpenAlex ID: W7143529331

FWCI:

Cites: 26

Cited by:

Related to: 10